Clinical Research Directory
Browse clinical research sites, groups, and studies.
Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease
Sponsor: Centenario Hospital Miguel Hidalgo
Summary
Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to function properly. People with chronic kidney disease (CKD) often experience chronic inflammation and digestive symptoms that may affect their quality of life. This study aims to evaluate whether daily supplementation with a synbiotic (a combination of probiotics and prebiotics) can reduce inflammation and improve gastrointestinal symptoms in adults with chronic kidney disease (CKD) stages 3 to 5 who are not receiving dialysis. Participants will be randomly assigned to receive either a synbiotic containing Lactobacillus rhamnosus, Bifidobacterium longum, and agave fructans, or a placebo, for a total of 16 weeks. Blood tests will be performed to measure inflammation, and participants will complete questionnaires related to digestive symptoms, quality of life, and dietary habits. The information obtained from this study may help improve nutritional strategies and supportive care for people living with chronic kidney disease.
Official title: Effect of a Synbiotic Containing Lactobacillus Rhamnosus, Bifidobacterium Longum, and Agave Fructans on High-Sensitivity C-Reactive Protein Levels in Patients With Predialysis Chronic Kidney Disease: A Double-Blind, Placebo-Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-03-01
Completion Date
2026-06-01
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
Synbiotic Supplement
Oral synbiotic supplement administered once daily for 16 weeks.
Placebo
Placebo identical in appearance, taste, and administration to the synbiotic supplement, administered once daily for 16 weeks.